ANZCTR search results

This study aims to compare the use of a robotic-assisted system and the current standard of care ultrasound-guided method for taking lung biopsy samples. Who is it for? You may be eligible for this study if you are aged 18 years or older and you are eligible to undergo an elective lung nodule biopsy at the Royal Brisbane & Womens Hospital. Study details All participants who choose to enrol in this study will have had a lung/chest CT scan taken prior to their enrolment. This scan will be used to plan how best the lung catheter and camera (bronchoscope) can be directed to collect samples of their lung tissue using the robotic-assisted bronchoscope (ION) System. Participants will be admitted as day patients at the Royal Brisbane & Womens Hospital and will undergo general anaesthesia in order to have the biopsy samples taken. It is anticipated that the procedure will take up to 45 minutes to complete. Once participants have recovered from the anaesthesia they will be able to go home. The samples taken by the robotic-assisted system will be processed to determine the likelihood that the tissue contains cancer cells. The results from an historical group of patients who had lung biopsies taken using the standard of care ultrasound-guided method will be used as a comparator to determine the safety and efficacy of the robotic-assisted method. It is hoped this research will determine whether use of the robotic-assisted system is able to provide more accurate tissue samples for assessment compared to the ultrasound-guided system. If the robotic-assisted system is found to be more effective and just as safe, if not safer, than the current standard of care method, use of the robotic-assisted system may be tested in a larger number of patients.

This study aims to determine whether patients with a high level of Amphiregulin/epiregulin (AREG/EREG) cancer cell markers for advanced stage colorectal cancer have a better treatment response to a combined chemo- and biological regime. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with right-sided RAS/BRAF wild type advanced stage colorectal cancer that has not been responsive to an initial treatment regime and you have previously provided a tumour sample for testing. Study details All participants who meet the inclusion criteria will firstly have their previously collected tumour sample tested to determine the level of AREG/EREG cancer cell markers present. Participants who have a high level of AREG and/or EREG cell markers will then begin a treatment regime that combines chemotherapy- irinotecan and biological therapy cetuximab. Treatment will occur every 14 days, in either of two ways- Intravenous infusion on Day 1, or intravenous infusion on Day 1 accompanied by 48 hr infusion pump. The treatment will be at physician discretion. The treatment will continue until disease progression, unacceptable toxicity or withdrawal of participant consent. Participants will be followed up for 3 years after beginning the treatment, unless they choose to withdraw from the study prior to that time. Participants who have a low level of AREG and EREG cell markers will be considered ineligible for participation in this study. It is hoped this research will determine whether the combination of cetuximab and irinotecan based treatment is effective for patients with a high level of AREG/EREG cancer cell markers of advanced stage colorectal cancer. If this treatment is found to be effective for participants with a high level of these markers, this method of screening colorectal patients may then be used more frequently to better prescribe treatments to specific patients.

In Australia, approximately one in ten children meet criteria for a neurodevelopmental condition. Neurodevelopmental conditions (NDCs) include Autism, Cerebral Palsy (CP), intellectual and learning disabilities. Impairments in cognition, communication, perception, and behaviour also frequently accompany both autistic individuals and those with CP. It is also common for children to have more than one NDCs. For example, of the one in 36 children that are diagnosed on the autism spectrum 88% will have additional co-occurring disability, commonly another NDC. Autism is also more prevalent in children with CP than it is in population studies, with studies estimating between 2% to 30% of children with CP also meet criteria for autism. Rates of mental health problems in adolescents with NDCs have also started to be explored. While 14% of all young people in Australia will experience a mental health condition, this compares to approximately 70% of autistic young people, over 40%-46% of young people with CP. However, unlike NDCs, most mental health conditions have the potential to be preventable, reversable or improved. Despite the additional support needs, interventions aimed at promoting wellbeing and mental health in adolescents with NDCs are extremely limited. The Westmead Feelings Program (WFP) was the first therapy program for children with NDCs aimed at improving emotional development skills with a focus on preventing mental illness. The Feelings Program for Adolescents (TFP-A) is the first program targeted at autistic adolescents with co-occurring mild ID and has also included adolescents with more significant communication and learning support needs. Previous studies of WFP and TFP-A report the programs to be feasible and enjoyable, and demonstrate improvements in emotional competence, and an increase in confidence for the parent and teacher in supporting social-emotional development. The present study involves The Feelings Program for Adolescents being delivered in a clinic-based or home-based setting, facilitated by CPA staff and parents. The primary purpose of the study is to explore the feasibility of TFP-A delivered in clinic and home-based settings, and efficacy of TFP-A in impacting emotional competence, social skills, problem behaviours, wellbeing and mental health of adolescents with NDCs. It is hypothesised that TFP-A will be found to be feasible in both settings, and will correlate with improvements in outcome measures including emotional competence, wellbeing and mental health in adolescents with NDCs.

Preclinical studies and clinical trials involving cannabidiol (CBD) have suggested potential efficacy in treatment of psychosocial stress, situational anxiety, and nausea. This study is a randomised, double-blinded, single-dose experimental trial that use a series of customised virtual reality (VR) experiences to investigate the effects of purified, oral cannabidiol (CBD) on subjective, endocrine, and physiological markers of: (1) acute psychosocial stress during a simulated public speaking task, (2) situational anxiety when walking a narrow plank above a sheer drop, (3) acute motion sickness induced by a virtual reality rollercoaster ride and (4) cybersickness induced by exposure to VR in healthy individuals. Participants will complete one experimental sessions involving either (1) CBD or (2) Placebo. Trials will be conducted at the Brain and Mind Centre, Camperdown. We hypothesise that CBD will improve ratings of psychosocial stress, situational anxiety and nausea.

This is a single-centre, randomised, double blind, single and multiple ascending dose study to assess the safety of ZE46-0134, and how this drug acts in the body in healthy volunteers. ZE46-0134 may be indicated for use in patients with leukaemia, but a trial of the drug in healthy volunteers is needed before trials in cancer patients can proceed. Who is it for? You may be eligible for this study if you are aged 18 to 55 years and are in good general health without a clinically significant medical history. People who have been diagnosed with cancer will not be eligible for this study. Study details All healthy volunteer participants who choose to enrol in this study will be assigned by chance to receive either a single or double dose of ZE46-0134 or placebo. All participants will have their vital signs checked (heart rate, blood pressure, temperature, etc), and will provide blood and urine samples for testing. If the drug appears safe, additional participants will be assigned by chance to receive a larger single dose of ZE46-0134 or placebo, followed by blood and urine testing. This will continue until a maximum safe dose is determined. It is hoped this research will determine the maximum dose of ZE46-0134 that can be administered safely without causing severe reactions. Once the dose of ZE46-0134 has been determined in healthy volunteers, a trial investigating the efficacy of ZE46-0134 as a treatment for patients with leukaemia may proceed.

Perceived cognitive difficulties are prevalent in people with mood and complex trauma. This includes difficulties in concentration, attention, planning and organisation, capacity to multitask, processing speed, and recall. The consequences of cognitive impairment include reduction in self-esteem, capacity to absorb information, and procrastination, as well as increases in the time necessary to complete tasks and avoidance of decision making. Such impairments can consequently impact individuals' performance at work, in relationships and in hobbies, and diminish the benefits of therapy. These circumstances necessitate the development of affordable and accessible interventions that can be offered to individuals experiencing cognitive function deficits associated with mood and trauma disorders. Cognitive training has been shown to be efficacious in aging populations, and populations with mild cognitive impairment, psychosis, and mood disorders. There is clear scope to develop and implement cognitive training for mood and complex trauma disorders in women's mental health. The research activities outlined in this application will specifically address the mental health needs of women with mood and complex trauma disorders. Gender differences in mental ill health are well documented. The proposed project seeks to improve symptoms of mood and complex trauma disorders in women by improving underlying problems in cognitive abilities. The outcomes of this cognitive training research will directly benefit women. The broader benefits of this research activity will help retain females in work and study, including perimenopausal women who often reduce their engagement in the workforce. Hence, this research activity will aid age and gender diversification and expertise in the modern workforce. The aim of this research is to design and implement a cognitive training program (COGtrain) tailored toward women’s mental health. That is, incorporating education about the influence of sex hormones and reproductive life events on mood and cognition. This research activity will employ an open-label feasibility trial design with the aims of (a) examining the feasibility of utilizing COGtrain among women with mood and complex trauma disorders and (b) determining whether COGtrain leads to significant improvements on measures of perceived cognitive impairment; neuropsychological and psychological functioning, and individual goal setting.

Current research indicates there may be an impact of bariatric surgery on patient’s psychological health, including increased rates of depression, suicidal and self-harm behaviours, and drug and alcohol use. However, the actual impact remains unclear due to the variety of procedures being performed, the diverse methods of assessing psychological health, and the amount of time patients are followed. In order to advance our understanding of these relationships, patients must be assessed and followed throughout their experience of bariatric surgery and for an extended amount of time into their recovery. This will facilitate the identification of risk factors so that the most vulnerable patients can be identified and the optimal care provided.

Reduced bone strength and increased fracture risk (osteoporosis) affects millions of older Australians, particularly women after menopause, resulting in massive burdens to society. Innovative research is desperately needed to address this. Exercise improves bone health however effects of combining exercise with bone-building medication are unknown and may lead to more effective collaborative treatment of osteoporosis. We are conducting a study in postmenopausal women with osteoporosis to determine whether a bone-building exercise programme can enhance effects of bone-building medication to improve bone mass over an 8-month period. We will assess whether 8-months combined osteoporosis drug therapy (romosozumab) with high-intensity exercise produces greater improvements in lumbar (lower) spine density compared to drug treatment with low-intensity exercise. The results will help determine whether doctors should prescribe bone-building exercise with drug therapy to enhance effectiveness of treatment in this priority population. This is the first randomised controlled trial initiating and combining drug and exercise treatment for osteoporosis and will provide important insights into the role of exercise in osteoporosis treatment. We will also assess whether romosozumab can improve muscle mass, strength and physical function compared to placebo, which may lead to reduction in falls which is important for people with osteoporosis given majority of fractures occur from falls. We expect that the combination of drug and exercise treatment will be the most effective strategy for improving lumbar spine bone density and that the drug will improve muscle mass, strength and physical function compared to placebo.

This study aims to determine the safety and feasibility of a combination of orally administered medications (naltrexone and bupropion) for people with methamphetamine use disorder in an outpatient drug and alcohol treatment setting. There are currently no approved medications in Australia to help people manage, reduce, or stop their methamphetamine use. It is hoped that this study will help find out if taking naltrexone and bupropion together everyday over a 12-week period is a safe and feasible treatment approach for methamphetamine use disorder .

Summary Our recent work has highlighted that the highest rates of type 2 diabetes are in Central Australia. The increasing numbers of Australian Aboriginal and Torres Strait Islander youth living with overweight, and obesity are contributing to increasing rates and earlier age of onset of type 2 diabetes (T2D) and related conditions. This program was developed in response to requests from NT communities and clinicians (Diabetes across Lifecourse Partnership Aboriginal and Torres Strait Islander Advisory Group, Clinical Reference Group and NT Diabetes Clinical Network) to address the issue of increasing rates of youth-onset obesity and diabetes. A key priority identified was for prevention, early detection and management of obesity and diabetes risk among Aboriginal youth. Australian childhood obesity prevention programs have previously had limited success in adapting to the needs of Aboriginal communities. In partnership with Central Australian Aboriginal Congress- (Congress), formative work in Central Australia was undertaken in 2019-2020 regarding the appropriateness of adapting an international youth diabetes prevention program successfully trialed in First Nations communities of North America (Tribal Turning Point). This work involved extensive consultation with a range of health service providers, family groups and cultural advisors. The next phase of this project involves implementing and evaluating the adapted Tribal Turning Point program (Merne Mwerre Artweye Areye-ke) in remote Australian (NT) communities to raise awareness and to prevent overweight/obesity and improve health among Aboriginal children and families. The cluster randomized trial will assess the clinical effectiveness and implementation of the Merne Mwerre Artweye Areye-ke Program in remote Australia for families with primary school aged children (6-11 years). It will run for 4 years from February 2023 to December 2026.